| Trial ID: | L6088 |
| Source ID: | NCT00526513
|
| Associated Drug: |
Insulin Glulisine
|
| Title: |
Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
|
| Acronym: |
SCALE
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Insulin Glulisine
|
| Outcome Measures: |
Primary: Glycosylated Haemoglobin (HbA1c), At 3 months after the treatment start|Glycosylated Haemoglobin (HbA1c), At 6 months after the treatment start | Secondary: Control of Fasting Blood Glucose (FBG), At 3 months after the treatment start|Control of Post-Prandial Glycemia (PPBG), At 3 months after the treatment start|Control of Post-Prandial Glycemia (PPBG), At 6 months after the treatment start
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
188
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-07
|
| Completion Date: |
2008-05
|
| Results First Posted: |
|
| Last Update Posted: |
2010-09-13
|
| Locations: |
Sanofi-Aventis Administrative Office, Cairo, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT00526513
|
